Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction
Journal of Virology, 2023
Duran-Castells C., Llano A., Kawana-Tachikawa A., Prats A., Martinez-Zalacain I., Kobayashi-Ishihara M., Oriol-Tordera B., Peña R., Gálvez C., Silva-Arrieta S., Clotet B., Riveira-Muñoz E., Ballana E., Prado J., Martinez-Picado J., Sanchez J., Mothe B., Hartigan-O’Connor D., Wyss-Coray T., Meyerhans A., Gisslén M., Price R., Soriano-Mas C., Muñoz-Moreno J., Brander C., Ruiz-Riol M.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Infectious Diseases | Patient Stratification | Plasma CSF |  Olink Target 96 |
Abstract
Neurocognitive disorders are frequently reported in people living with HIV (PLWH) even with the introduction of combined antiretroviral treatment (cART). To identify biomarkers and potential therapeutic tools to target HIV infection in peripheral blood and in the central nervous system (CNS), plasma proteomics were applied in untreated chronic HIV-infected individuals with different levels of virus control.